Literature DB >> 19066597

Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro.

Maria P Limberis1, Luk H Vandenberghe, Liqun Zhang, Raymond J Pickles, James M Wilson.   

Abstract

We have characterized the ability of adeno-associated virus (AAV) serotypes 1-9 in addition to nineteen novel vectors isolated from various tissues, to transduce mouse and human ciliated airway epithelium (HAE). Vectors expressing alpha-1-antitrypsin (AAT) and beta-galactosidase were co-instilled into the mouse lung. Of all the vectors tested rh.64R1, AAV5 and AAV6 were the most efficient. The high transduction observed in mouse was reproduced in HAE cell cultures for both rh.64R1 and AAV6 but not for AAV5. Since AAV6 was the most efficient vector in mouse and HAE we also tested the transduction efficiencies of the AAV6 singleton vectors (i.e., AAV6 variants with targeted mutations) in these models. Of these, AAV6.2 transduced mouse airway epithelium and HAE with greater efficiency than all other AAV vectors tested. We demonstrated that AAV6.2 exhibits improved transduction efficiency compared to previously reported AAVs in mouse airways and in culture models of human airway epithelium and that this vector requires further development for preclinical and clinical testing.

Entities:  

Mesh:

Year:  2008        PMID: 19066597      PMCID: PMC2835069          DOI: 10.1038/mt.2008.261

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  39 in total

1.  Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium.

Authors:  Liqun Zhang; Alexander Bukreyev; Catherine I Thompson; Brandy Watson; Mark E Peeples; Peter L Collins; Raymond J Pickles
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study.

Authors:  J F Engelhardt; R H Simon; Y Yang; M Zepeda; S Weber-Pendleton; B Doranz; M Grossman; J M Wilson
Journal:  Hum Gene Ther       Date:  1993-12       Impact factor: 5.695

3.  Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus.

Authors:  J A Wagner; T Reynolds; M L Moran; R B Moss; J J Wine; T R Flotte; P Gardner
Journal:  Lancet       Date:  1998-06-06       Impact factor: 79.321

4.  Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue.

Authors:  D Duan; P Sharma; J Yang; Y Yue; L Dudus; Y Zhang; K J Fisher; J F Engelhardt
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

Review 5.  Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective.

Authors:  Barrie J Carter
Journal:  Mol Ther       Date:  2004-12       Impact factor: 11.454

6.  Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer.

Authors:  R J Pickles; D McCarty; H Matsui; P J Hart; S H Randell; R C Boucher
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

7.  Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung.

Authors:  C K Conrad; S S Allen; S A Afione; T C Reynolds; S E Beck; M Fee-Maki; X Barrazza-Ortiz; R Adams; F B Askin; B J Carter; W B Guggino; T R Flotte
Journal:  Gene Ther       Date:  1996-08       Impact factor: 5.250

8.  Adeno-associated virus vectors preferentially transduce cells in S phase.

Authors:  D W Russell; A D Miller; I E Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

Review 9.  Pathophysiology of gene-targeted mouse models for cystic fibrosis.

Authors:  B R Grubb; R C Boucher
Journal:  Physiol Rev       Date:  1999-01       Impact factor: 37.312

10.  Mucociliary differentiation of serially passaged normal human tracheobronchial epithelial cells.

Authors:  T E Gray; K Guzman; C W Davis; L H Abdullah; P Nettesheim
Journal:  Am J Respir Cell Mol Biol       Date:  1996-01       Impact factor: 6.914

View more
  77 in total

1.  Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques.

Authors:  Karen Nieto; Christiane Stahl-Hennig; Barbara Leuchs; Martin Müller; Lutz Gissmann; Jürgen A Kleinschmidt
Journal:  Hum Gene Ther       Date:  2012-04-18       Impact factor: 5.695

2.  Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro.

Authors:  Anna R Kwilas; Mark A Yednak; Liqun Zhang; Rachael Liesman; Peter L Collins; Raymond J Pickles; Mark E Peeples
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

3.  Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease.

Authors:  Christian M Brommel; Ashley L Cooney; Patrick L Sinn
Journal:  Hum Gene Ther       Date:  2020-08-21       Impact factor: 5.695

Review 4.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

5.  Capsid antibodies to different adeno-associated virus serotypes bind common regions.

Authors:  Brittney L Gurda; Michael A DiMattia; Edward B Miller; Antonette Bennett; Robert McKenna; Wendy S Weichert; Christian D Nelson; Wei-jun Chen; Nicholas Muzyczka; Norman H Olson; Robert S Sinkovits; John A Chiorini; Sergei Zolotutkhin; Olga G Kozyreva; R Jude Samulski; Timothy S Baker; Colin R Parrish; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-06-12       Impact factor: 5.103

6.  CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes.

Authors:  Benjamin Steines; David D Dickey; Jamie Bergen; Katherine Jda Excoffon; John R Weinstein; Xiaopeng Li; Ziying Yan; Mahmoud H Abou Alaiwa; Viral S Shah; Drake C Bouzek; Linda S Powers; Nicholas D Gansemer; Lynda S Ostedgaard; John F Engelhardt; David A Stoltz; Michael J Welsh; Patrick L Sinn; David V Schaffer; Joseph Zabner
Journal:  JCI Insight       Date:  2016-09-08

Review 7.  Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies.

Authors:  James L Kreindler
Journal:  Pharmacol Ther       Date:  2009-11-10       Impact factor: 12.310

8.  Syndecan-1 Attenuates Lung Injury during Influenza Infection by Potentiating c-Met Signaling to Suppress Epithelial Apoptosis.

Authors:  Rena Brauer; Lingyin Ge; Saundra Y Schlesinger; Timothy P Birkland; Ying Huang; Tanyalak Parimon; Vivian Lee; Bonnie L McKinney; John K McGuire; William C Parks; Peter Chen
Journal:  Am J Respir Crit Care Med       Date:  2016-08-01       Impact factor: 21.405

Review 9.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

Review 10.  Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease.

Authors:  Maria J Chiuchiolo; Ronald G Crystal
Journal:  Ann Am Thorac Soc       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.